N/A N=6,013 Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake
Cervical Intraepithelial Neoplasia
Primary: Screening Uptake — 2519; 0; 2618; 599 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
N/A N=51 Psychosocial Outcomes in Online Cancer Support Groups
Breast Cancer
Primary: Scores on the Personal Resource Questionnaire 85. — 50.22; 53.44 Scores on a scale — p=.315
N/A N=155 Increasing African Immigrant Women's Participation in Breast Cancer Screening
Breast Cancer
Primary: Mammogram Intention — 1.90 score on a scale
N/A N=9 Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma
HIV
Primary: Peak Plasma Concentration of Etravirine in Plasma — 497.6 ng/ml
N/A N=271 Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
Breast Neoplasms · Early Detection of Cancer
Primary: Percentage of Women Who Completed a Breast MRI and Mammogram — 8.9; 22.0; 17.8 percentage of participants — p=0.019
N/A N=12 Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Chronic Myelomonocytic Leukemia-2 · Myelodysplastic Syndrome · Myeloproliferative Neoplasm
Primary: Overall Survival of Patients Over Age 60 With Newly Diagnosed AML/High Risk MDS — 7 participants
Phase 3 N=131 Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction
Breast Cancer · Pain, Postoperative · BRCA1 Mutation
Primary: Change From Baseline in Average Pain Scores Using a Numeric Pain Intensity Scale — 2; 3 score on a scale — p=0.43
Phase 2 N=46 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Breast Neoplasms
Primary: Percent Change in Mammographic Density at 1 Year on Exemestane — -2.4 percent change from baseline
Phase 2 N=24 Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
Breast Cancer
Primary: Estimate Efficacy of Capecitabine 7/7 in Combination With Lapatinib in Patients With HER2 Overexpressed/Amplified, Trastuzumab-refractory, Metastatic Breast Cancer as…
N/A N=54 External-Beam Partial-Breast Irradiation for Early Breast Cancer 40 Gy QD Over 2 Weeks
Breast Cancer
Primary: Safety of External-beam PBI Utilizing 40Gy in Ten Daily Fractions Over Two Weeks — 0; 0; 0; 0 Participants
N/A N=1,436 Implementing Systematic Distress Screening in Breast Cancer
Breast Cancer
Primary: Number of Participants Offered and Screened for Distress — 596; 3 Participants
Phase 2 N=72 Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
Breast Cancer
Primary: Change in Ki-67 Levels From Baseline (Pre) to Day 28 (Post) Biopsy Samples — -1.3632; -1.6237 log-transformed Ki67% — p=0.6202
N/A N=34,047 Behavioural Science Messages in Breast Cancer Screening
Breast Cancer
Primary: No. of Participants Taking up Breast Cancer Screening at Three Months- Intention to Treat — 2225; 2064; 2137 participants
N/A N=153 Addressing the Health Concerns of VA Women With Sexual Trauma
Stress Disorders, Post-Traumatic · Intimate Partner Violence · Alcohol-Related Disorders
Primary: Change in Number of Health Risks — 1.38; 1.05 number of risks